异长春花碱联合顺铂治疗晚期NSCLC的研究

目的观察异长春花碱(Vinorelbine,NVB)联合顺铂(Cisplatin,DDP)治疗晚期非小细胞肺癌(NSCLC)的近期、远期疗效和毒副反应。方法110例晚期NSCLC患者。化疗方案:NVB 25～30mg/m2,静注,第1、8天,DDP 50mg/m2,静滴,第2、3天;3～4周为1周期。结果NVB加DDP治疗NSCLC有效率为35.24%,临床受益率78.09%;初治与复治有效率分别为41.06%和18.52%, 差异有显著性意义(P<0.05),初治与复治的临床受益率差异无显著性意义(P>0.05);治疗后中位缓解期为20周;中位生存期为38周;一年生存率为32.73%。主要毒副反应Ⅲ-Ⅳ度恶心/呕吐发生率31.82%,Ⅲ-Ⅳ度白细胞抑制率32.73%,Ⅲ-Ⅳ度便秘发生率34.56%,静脉炎发生率50.91%。结论异长春花碱加顺铂治疗晚期NSCLC,有较好的近期疗效和远期疗效,恶心/ 呕吐和骨髓抑制和其它毒副反应可耐受,是治疗晚期NSCLC的一线化疗方案。

Vinorelbine plus Cisplatin Combintion Treatmcnt of Advanced Non- Small Cell Lung Cancer

Objective To evaluate the curative and side effects of vinorelbine (NVB) plus cisplation (DDP) on advanced non- small cell lung cancer (NSCLC) . Methods A total of 110 caes with advanced NSCLC were enrolled in study. All the patients were received NVB 25 - 30mg/ m2 d_1 and d_8 and DDP 50mg/m~2 d_2 and d_3 every 3 - 4 weeks. The whole course of treatment consisted of at least 2 cycles. Results The response and the clinical beneficial rates (CBR) were 35.24% and 78.09% respectively.The response rate in the first treated patients was 41.06% which was significantly higher than that (18.25%) in the retreated patients ( P < 0.05) .The CBR in the first treated patients was 79.49% which was insignificantly different from that (74.07%) in the retreated patients ( P > 0.05). The median time of remission and median survival time.and 1 year survival rate were 20 weeks,38 weeks and 32.73% respectively. The major toxicities included nausea/vomiting, neutropenia.constipation, phlebitis and peripheral neuritis. Conclusions NVB plus DDP is a safe, effective and well - tolerated regimen in the patients with advance NSCLC. The regimen may be the first chemotherapy selection in the patients with advanced NSCLC.